Clinical trials bureaucracy: Unintended consequences of well-intentioned policy

Clinical Trials

Volumn 3, Issue 6, 2006, Pages 496-502

  Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG APPROVAL; ETHICS COMMITTEES, RESEARCH; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34447314711     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774506073173     Document Type: Conference Paper

References (40)

1. MRC Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; ii: 769-778.
2. Yusuf S. Randomized clinical trials: Slow death by a thousand unnecessary policies? CMAJ 2004; 17: 889-892.
3. Temple RJ. The effect of the Drug Regulation Reform Act of 1978 on clinical research, drug availability, and the public health. Ann N Y Acad Sci 1981; 368: 175-185.
4. Temple R, Pledger GW. The FDA' s critique of the anturane reinfarction trial. N Engl J Med 1980; 303: 1488-1492.
5. Capron AM. When experiments go wrong: The U.S. perspective. J Clin Ethics 2004; 15: 22-29.
6. Smith L, Byers JF. Gene therapy in the post-Gelsinger era. JONAS Healthc Law Ethics Regul 2002; 4: 104-110.
7. Anon. OHRP orders Johns Hopkins University to suspend human subjects research. J Investig Med 2001; 49: 379-379.
8. Califf RM, Morse MA, Wittes J et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24: 256-271.
9. Califf RM, Peterson ED, Gibbons RJ et al. Integrating quality of care into the cycle of therapeutic development. J Am Coll Cardiol 2002; 40: 1895-1901.
10. Gibbons RJ, Smith S, Antman E; American College of Cardiology; American Heart Association. American College of Cardiology/American HeWrt Association clinical practice guidelines: Part I: where do they come from? Circulation 2003; 107: 2979-2986.
11. Gibbons RJ, Smith SC Jr, Antman E; American College of Cardiology; American Heart Association. American College of Cardiology/American HeaEt Association clinical practice guidelines: Part II: evolutionary changes in a continuous quality improvement project. Circulation 2003; 107: 3101-3107.
12. Bufalino V, Peterson ED, Burke GL et al. Payment for quality: Guiding principles and recommendations: Principles and recommendations from the American Heart Association' s Reimbursement, Coverage, and Access Policy Development Workgroup. Circulation 2006; 113: 1151-1154.
13. Peterson ED, Roe MT, Mulgund J et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006; 295: 1912-1920.
14. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part I. Circulation 2002; 106: 746-751.
15. Pattison J, Stacey T. Research bureaucracy in the United Kingdom: seeking a balance: Response from the Department of Health and COREC. Br Med J 2004; 329: 622-622.
16. Moses H 3rd, Dorsey ER, Matheson DH, Thier SO. Financial anatomy of biomedical research. JAMA 2005; 294: 1333-1342.
17. Woodcock J. An audience with Janet Woodcock discusses the role of the FDA in improving pharma productivity. Nat Rev Drug Discov 2004; 3: 904-904.
18. Morganroth J, Bigger JT Jr. Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial. Am J Cardiol 1990; 65: 1497-1503.
19. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
20. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women' s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
21. Marks AR. Rescuing the NIH before it is too late. J Clin Invest 2006; 116: 844-844.
22. March J, Silva S, Petrycki S et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807-820.
23. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-1448.
24. Begg CB, Brawley O, Califf RM, Demets DL, Ellenberg SS, Kaplan RS. Marketing drugs too early in testing. Science 2006; 312: 195 - 195.
25. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel' s back: multicenter clinical trials and local institutional review boards. Ann Intern Med 2001; 134: 152-157.
26. Jamrozik K. Research ethics paperwork: What is the plot we seem to have lost? Br Med J 2004; 329: 286-287.
27. Peto J, Fletcher O, Gilham C. Data protection, informed consent, and research. Br Med J 2004; 328: 1029-1030.
28. Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA 2001; 285: 1201-1205.
29. Sugarman J, Lavori PW, Boeger M et al. Evaluating the quality of informed consent. Clin Trials 2005; 2: 34-41.
30. Weinfurt KP, Dinan MA, Allsbrook JS et al. Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants. Acad Med 2006; 81: 113-118.
31. Ellenberg S, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: A practical perspective (statistics in practice). John S Wiley and Sons, 2003.
32. DeMets DL, Fleming TR, Rockhold F et al. Liability issues for data monitoring committee members. Clinical Trials 2004; 1: 525-531.
33. Gross R, Strom BL. Toward improved adverse event/suspected adverse drug reaction reporting. Pharmacoepidemiol Drug Saf 2003; 12: 89-91.
34. Chilappagari S, Kulkarni A, Bolich-Aldrich S et al. A statistical process control method to monitor completeness of central cancer registry reporting data. J Registry Mgt 2002; 4: 121-127.
35. Svolba G, Bauer P. Statistical quality control in clinical trials. Cont Clin Trials 1999; 20: 519-530
36. Nahm M. Optimizing data quality through statistical process control. 15th Annual US DIA Clinical Data Management Symposium: Innovative Technologies and Strategies for the Global Management of Clinical Data. 14-17 March 2000, Philadelphia, Pennsylvania, USA.
37. Rostami R. Optimized clinical trial data quality checks using SPC. 14th Annual European Clinical Data Management Conference, DIA. 8-10 November 2004, Amsterdam, The Netherlands.
38. Eisenstein EL, Lemons PW 2nd, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J 2005; 149: 482-488.
39. Ferris L, Naylor CD. Physician remuneration in industry-sponsored clinical trials: The case for standardized clinical trial budgets. CMAJ 2004; 171: 883-886.
40. Schulman KA, Seils DM, Timbie JW et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 2002; 347: 1335-1341.